|Day Low/High||21.83 / 22.41|
|52 Wk Low/High||15.44 / 29.41|
Ocular Therapeutix, Alder BioPharmaceuticals, Flexion Therapeutics were among the biotech stock movers in premarket trading on July 12.
There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.
Bold culture earns company recognition in medium business category
Investors in Flexion Therapeutics, Inc. saw new options begin trading this week, for the February 2018 expiration.
Coherus BioSciences, XBiotech and Flexion Therapeutics were among the biotech stock movers in premarket trading on Monday.
Full findings from Phase 2 study in patients with knee osteoarthritis and Type 2 diabetes show Zilretta avoids the significant rise in blood glucose seen with an immediate-release corticosteroid
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
The most recent short interest data was recently released for the 05/15/2017 settlement date, and Flexion Therapeutics, Inc. is one of the most shorted stocks of the Russell 3000, based on 5.76 "days to cover" versus the median component at 4.71.
The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 2,281,535 share increase in total short interest for Flexion Therapeutics, Inc. , to 4,478,675, an increase of 103.84% since 04/28/2017.
Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.
Presentation to include full results from Phase 2 study evaluating Zilretta™ (FX006) in patients with Type 2 diabetes and osteoarthritis of the knee
Investors in Flexion Therapeutics, Inc. saw new options begin trading this week, for the November 17th expiration.
Akebia after the market close on Tuesday announced an expanded partnership with Japan's Otsuka Pharmaceuticals to develop and market its anemia pill Vadadustat in Europe, China and other territories.
This is one of those days when it may pay to walk away.
New Patents Cover Method of Use and Method of Manufacturing